D-0543-2024 Class III Ongoing

Recalled by Zydus Pharmaceuticals (USA) Inc — Pennington, NJ

FDA drug recall D-0543-2024 was initiated by Zydus Pharmaceuticals (USA) Inc on May 16, 2024 and is designated Class III. Reason for recall: Failed Impurities/Degradation Specifications. The recall status is ongoing. Affected quantity: 13,440 units.

Recall details

Product Type
Drugs
Report Date
Jun 12, 2024
Initiation Date
May 16, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
13,440 units

Product description

Estradiol Transdermal System, USP (Twice-Weekly) 0.025mg/day, Rx Only, Manufactured by: Cadila Healthcare Limited, Ahmedabad, India, Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534, NDC 70710-1191-8

Reason for recall

Failed Impurities/Degradation Specifications.

Distribution pattern

Nationwide within the United States

Code information

Lot #: M311202, Exp. Date 2/25; M311201, Exp. Date 1/25

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0543-2024
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0543-2024. Report a data issue: hello@regdatalab.com.